GSK (formerly called GlaxoSmithKline) has acquired rights to HS235, an experimental treatment for pulmonary hypertension (PH), now in early clinical testing, that the buyer hopes will become a new standard of care for PH. The therapy’s developer 35Pharma announced that it’s being acquired by GSK for $950…
News
Global advocacy group Phaware has launched a new app, called Heart Works – phaware, to provide a centralized hub for education, health tracking, and community connection for those living with pulmonary hypertension (PH). The app is designed to…
People with pulmonary arterial hypertension (PAH) who were treated with the inhaled therapy seralutinib in a clinical trial tended to have better improvements in exercise capacity than those given a placebo, data show. However, the difference between the groups failed to meet a prespecified threshold for statistical significance. That…
In pulmonary arterial hypertension (PAH), blood vessel cells in the lungs release exosomes, or cellular shipping containers, filled with a signaling molecule called microRNA-21 (miR-21) that are taken up by heart cells to help limit heart damage, a new study shows. “These findings identify exosomal miR-21 as a key…
Treatment with molecular shipping containers called extracellular vesicles, loaded with a signaling molecule called cAMP, reduced the severity of pulmonary hypertension (PH) in a rat model of the disease, a new study reports. The data indicated that these packages of signaling molecules, which they dubbed cAMP-EVs, reduced the abnormal…
The one-minute sit-to-stand test (STST), which measures the number of times a patient can sit down and stand up from a chair in 1 min, may predict adverse outcomes in adults with pulmonary hypertension (PH), according to a study. In particular, worse performance in the STST (14 repetitions or…
Mutations in the gene SOX17 are linked to a severe form of pulmonary arterial hypertension (PAH) that most often manifests in childhood, though these mutations are also found in some adults with adult-onset PAH, according to a new study. Findings suggest that the specific type and location of mutations in…
Researchers using computational analyses of genetic data have identified three age-related proteins that may play key roles in the progression of pulmonary hypertension (PH), along with a small molecule that may be able to target these proteins. “This work provides the first model for aging-related PH diagnosis and points…
A lack of the protein beta-arrestin 1 reduces the ability of pulmonary arteries to widen, leading to pulmonary hypertension (PH), according to a new study in mice. The study found that when beta-arrestin 1 is missing, the signaling pathway that drives the widening of pulmonary arteries, the blood vessels…
A clinical trial testing mosliciguat, an inhaled therapy for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), has wrapped up enrollment, and in less than one year since treating the first participant. That announcement was made by Pulmovant, the company developing the drug…
Cereno Scientific announced it will broaden development of its experimental treatment CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno had previously focused development of CS014 on idiopathic pulmonary fibrosis (IPF), a condition marked by progressive scarring (fibrosis) of the lungs with no known…
Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s hospital stay following surgery among people with chronic thromboembolic pulmonary hypertension (CTEPH). As such, these tools could potentially be used to improve patient care, and better monitor post-surgery recovery,…
